Challenges and hopes in CRISPR CAS technology in future
- 19 August 2021
- journal article
- Published by Scientific Advanced Learning Technologies Trust in SALT Journal of Scientific Research in Healthcare
Abstract
Genome editing is a flourishing tool that tends to be a boon for scientists to change an organism's DNA. With genome editing technology, scientists can add, remove or alter DNA, resulting in the inactivation of target genes, acquisition of novel genetic traits, and correction of pathogenic gene mutations. Different approaches were developed to edit the genome; one among them is CRISP-Cas which was recently developed. CRISPR associated proteins (CRISPR/Cas) are genome editing systems originated from prokaryotes that have allowed researchers to identify, photograph, alter, and annotate specific DNA and RNA sequences in a variety of living cells. Since using CRISPR/Cas is of low cost with high efficiency and good repeatability with a short cycle, it is used globally for genome editing. In the review, we analysed the utilisation of CRISPR/Cas as therapeutics to cure deadly diseases such as AIDS, Hepatitis B and human papillomavirus infection. Since CRISPR/Cas is cost-effective genome editing, the challenges to be faced in future due to usage of CRISPR/Cas and the areas where it can be utilised were discussed briefly in this review. Key message: Genetic technology, genome editing, editing tool, CRISPR/Cas, cost-effective, therapeutics.Keywords
This publication has 62 references indexed in Scilit:
- Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cellsNucleic Acids Research, 2013
- Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteriaProceedings of the National Academy of Sciences of the United States of America, 2012
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Occult HBV infectionSeminars in Immunopathology, 2012
- RNA-guided genetic silencing systems in bacteria and archaeaNature, 2012
- CRISPR RNA maturation by trans-encoded small RNA and host factor RNase IIINature, 2011
- CRISPR/Cas, the Immune System of Bacteria and ArchaeaScience, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Papillomaviruses in the causation of human cancers — a brief historical accountVirology, 2009
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerThe New England Journal of Medicine, 2003